Deger, Teoman
Boers, Ruben G.
de Weerd, Vanja
Angus, Lindsay
van der Put, Marjolijn M. J.
Boers, Joachim B.
Azmani, Z.
van IJcken, Wilfred F. J.
Grünhagen, Dirk J.
van Dessel, Lisanne F.
Lolkema, Martijn P. J. K.
Verhoef, Cornelis
Sleijfer, Stefan
Martens, John W. M.
Gribnau, Joost
Wilting, Saskia M.
Article History
Received: 27 April 2021
Accepted: 10 September 2021
First Online: 20 October 2021
Declarations
:
: Coded metastatic cancer patient samples were obtained from various clinical studies (MEC 17-238, MEC 15-289, and MEC 16-499), all of which were approved by the Medical Ethics Committee from the Erasmus University Medical Center. All patients signed an informed consent.
: Not applicable.
: The authors declare no conflict of interest or financial interests except for RB, JB, WvIJ, and JG, who report being shareholder in Methylomics B.V., a commercial company that applies MeD-seq to develop methylation markers for cancer staging.